No Data
The stock price has plummeted. Hunan Jiudian Pharmaceutical responded: The market has reported that Wangaoyao Fluorofen Gel Patch has received acceptance of its listing application, which may have caused fluctuations.
Gelonghui, December 30th | Hunan Jiudian Pharmaceutical's share price dropped over 17% in the morning. A reporter contacted Hunan Jiudian Pharmaceutical's investor relations department regarding the decline in stock price, and a related person stated that the company's operations are normal. There are market reports that Jiangsu Wangao Pharmaceutical Co., Ltd.’s application for the上市 of flurbiprofen gel patches has been accepted, but there is no result yet whether it will be approved, which may have caused fluctuations in the stock price. December's investor relations management information shows that Hunan Jiudian Pharmaceutical expects the flurbiprofen gel patches to be approved in 2025 and the external preparation flurbiprofen patches to be approved in 2026. So, Wangao Pharmaceutical’s acceptance of the flurbiprofen gel patches listing application will have an effect on Hunan Jiudian Pharmaceutical.
Hunan Jiudian Pharmaceutical (300705.SZ): The company has ideas for external acquisition.
Gelonghui, December 17 - Hunan Jiudian Pharmaceutical (300705.SZ) recently stated during an investor relations event that the company has plans for external mergers and acquisitions and is currently looking for symbols that match its Global Strategy.
Hunan Jiudian Pharmaceutical (300705.SZ): The sales of Loxoprofen sodium gel patches are currently less affected by external pricing policies.
Gelonghui reported on December 17 that Hunan Jiudian Pharmaceutical (300705.SZ) recently stated in an investor relations activity that the sales of its Loxoprofen Sodium Gel Patch are currently less affected by the external pricing policy, with prices being largely consistent between hospitals and outside the hospital (both online and offline).
Hunan Jiudian Pharmaceutical (300705.SZ): The net income after deducting non-recurring items for the year 2024 is expected to grow by 30-40% year-on-year.
On December 17, Gelonghui reported that Hunan Jiudian Pharmaceutical (300705.SZ) indicated in a recent investor relations activity that the company's revenue for 2024 is expected to grow by 10-20% year-on-year, and the net income excluding non-recurring items is expected to increase by 30-40%. For specifics, please refer to the company's disclosed financial budget report for 2024.
Express News | Summary of Shareholding reductions by listed companies on December 16.
Express News | Ping An Securities Pharmaceutical Industry 2025 Annual Strategy Report: Exploring new growth from payment sources, focusing on innovation, going overseas, equipment upgrades, and Consumer recovery.
No Data
